Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v3-FR
Language French French
Date Updated 2022-05-27 2022-05-13
Drug Identification Number 02145766 02145766
Brand name VISIPAQUE 270 VISIPAQUE 270
Common or Proper name iodixanol injection USP iodixanol injection USP
Company Name GE HEALTHCARE CANADA INC GE HEALTHCARE CANADA INC
Ingredients IODIXANOL IODIXANOL
Strength(s) 550MG 550MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRA-ARTERIAL INTRA-ARTERIAL INTRAVENOUS INTRAVENOUS INTRA-ARTERIAL INTRA-ARTERIAL INTRAVENOUS
Packaging size 200 mL 200 mL
ATC code V08AB V08AB
ATC description X-RAY CONTRAST MEDIA, IODINATED X-RAY CONTRAST MEDIA, IODINATED
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2022-07-15 2022-07-15
Actual start date 2022-05-26
Estimated end date Unknown Unknown
Actual end date
Shortage status Actual shortage Anticipated shortage
Tier 3 Status No No
Company comments Covid Related Shutdown in China. This is a fluid situation that we are working through daily. We will keep all customers informed on what orders to expect during this period so they can plan accordingly. Covid Related Shutdown in China. This is a fluid situation that we are working through daily. We will keep all customers informed on what orders to expect during this period so they can plan accordingly.
Health Canada comments